secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K/A
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0001104659-23-068973
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals raises ~$6.28M in registered direct offering with warrants at $0.65/share
--------------------------------------------------------------------------------

- Gross proceeds of ~$6.28M; 9,670,002 shares sold at $0.65/share with warrants to purchase equal shares at $0.6525.
- Warrants exercisable 6 months after closing, expire 5.5 years from issuance; no future price adjustment except stock splits.
- Existing warrants (Aug 2021/Feb 2022, $3.07–$12.00) amended to $0.6525 exercise price, exercisable after 6 months, extended to 5.5 years.
- Proceeds for working capital, potential NRX-101 PTSD/chronic pain research; company plans to service current debt on interest basis through 2023.
- H.C. Wainwright acts as exclusive placement agent, receiving 6.5% cash fee and 2% warrant coverage of shares placed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923068973/0001104659-23-068973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465923068973/tm2317653d6_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-068973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer